NVP-BEZ235, a dual inhibitor of PI3K and mTOR, induces MAPK phosphorylation in HER2 positive cells

被引：0
|
作者：
Serra, Violeta [1 ]
Eichhorn, Pieter [1 ]
Scaltriti, Maurizio [1 ]
Prudkin, Ludmila [1 ]
Rodriguez, Olga [1 ]
Guzman, Marta [1 ]
Baselga, Jose [1 ]
机构：
[1] Vall dHebron Inst Oncol, Barcelona, Spain
来源：
CANCER RESEARCH | 2009年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB-52
引用
收藏
页数：1
相关论文
共 50 条
  • [41] The dual PI3K/mTOR blocker NVP-BEZ235 sensitizes cancer cells against irreversible ErbB inhibitors
    Grunt, T. W.
    Bruenner-Kubath, C.
    Shabbir, W.
    Saferding, V.
    Wagner, R.
    Singer, C. F.
    Valent, P.
    Berger, W.
    Zielinski, C. C.
    Grusch, M.
    EJC SUPPLEMENTS, 2010, 8 (07): : 43 - 43
  • [42] The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer
    Awasthi, Niranjan
    Yen, Peter L.
    Schwarz, Margaret A.
    Schwarz, Roderich E.
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2012, 113 (03) : 784 - 791
  • [43] In vivo antitumor activity of NVP-BEZ235, a dual PI3K/mTOR inhibitor, and RAD001 (everolimus), an mTOR inhibitor, in endometrial cancer
    Shoji, Keiko
    Oda, Katsutoshi
    Nakagawa, Shunsuke
    Ikeda, Yuji
    Kashiyama, Tomoko
    Miyamoto, Yuichiro
    Tanikawa, Michihiro
    Kuramoto, Hiroyuki
    Hiraike-Wada, Osamu
    Yano, Tetsu
    Taketani, Yuji
    CANCER RESEARCH, 2011, 71
  • [44] The combination of gemcitabine with the dual PI3K/mTOR-inhibitor NVP-BEZ235 in human pancreatic cancer cell lines
    Glienke, W.
    Hausmann, E.
    Wicht, J.
    Maute, L.
    Bergmann, L.
    ONKOLOGIE, 2011, 34 : 57 - 58
  • [45] Genotype-Dependent Efficacy of a Dual PI3K/mTOR Inhibitor, NVP-BEZ235, and an mTOR Inhibitor, RAD001, in Endometrial Carcinomas
    Shoji, Keiko
    Oda, Katsutoshi
    Kashiyama, Tomoko
    Ikeda, Yuji
    Nakagawa, Shunsuke
    Sone, Kenbun
    Miyamoto, Yuichiro
    Hiraike, Haruko
    Tanikawa, Michihiro
    Miyasaka, Aki
    Koso, Takahiro
    Matsumoto, Yoko
    Wada-Hiraike, Osamu
    Kawana, Kei
    Kuramoto, Hiroyuki
    McCormick, Frank
    Aburatani, Hiroyuki
    Yano, Tetsu
    Kozuma, Shiro
    Taketani, Yuji
    PLOS ONE, 2012, 7 (05):
  • [46] Effect of the combination of the dual mTOR/pI3K inhibitor NVP-BEZ235 with gemcitabine on growth inhibition in pancreatic cancer cells in vitro and in vivo
    Maute, Luise
    Wicht, Johannes
    Zoernig, Martin
    Niederhagen, Manuel
    Bergmann, Lothar
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [47] PI3K and mTOR inhibitor, NVP-BEZ235, is more toxic than X-rays in prostate cancer cells
    Maleka, S.
    Serafin, A. M.
    Akudugu, J. M.
    INTERNATIONAL JOURNAL OF RADIATION RESEARCH, 2019, 17 (01): : 37 - 45
  • [48] Activity of dual PI3K/mTOR inhibitor, NVP-BEZ235, and mTOR inhibitor, RAD001 (everolimus), in endometrial cancer cell lines.
    Shoji, K.
    Oda, K.
    Nakagawa, S.
    Ikeda, Y.
    Kuramoto, H.
    Nishida, N.
    Kawana, K.
    Yano, T.
    Kozuma, S.
    Taketani, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [49] The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer
    Zhang, Chang-Hua
    Awasthi, Niranjan
    Schwarz, Margaret A.
    Schwarz, Roderich E.
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2013, 43 (05) : 1627 - 1635
  • [50] Radiosensitization of Glioblastoma Cell Lines by the Dual PI3K and mTOR Inhibitor NVP-BEZ235 Depends on Drug-Irradiation Schedule
    Kuger, Sebastian
    Graus, Dorothea
    Brendtke, Rico
    Guenther, Nadine
    Katzer, Astrid
    Lutyj, Paul
    Polat, Buelent
    Chatterjee, Manik
    Sukhorukov, Vladimir L.
    Flentje, Michael
    Djuzenova, Cholpon S.
    TRANSLATIONAL ONCOLOGY, 2013, 6 (02): : 169 - U243
12345